Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Feb-Mar;24(1):27-33.
doi: 10.1177/1533317508325094. Epub 2008 Dec 3.

Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study

Affiliations
Randomized Controlled Trial

Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study

Ruth Remington et al. Am J Alzheimers Dis Other Demen. 2009 Feb-Mar.

Abstract

Recent studies demonstrated efficacy of a vitamin/ nutriceutical formulation (folate, vitamin B12, alpha-tocopherol, S-adenosyl methionine, N-acetyl cysteine, and acetyl-L-carnitine) for mild to moderate Alzheimer's disease. Herein, we tested the efficacy of this formulation in a small cohort of 12 institutionalized patients diagnosed with moderate-stage to later-stage Alzheimer's disease. Participants were randomly separated into treatment of placebo groups. Participants receiving the formulation demonstrated a clinically significant delay in decline in the Dementia Rating Scale and clock-drawing test as compared to those receiving placebo. Institutional caregivers reported approximately 30% improvement in the Neuropyschiatric Inventory and maintenance of performance in the Alzheimer's Disease Cooperative Study-Activities of Daily Living for more than 9 months. This formulation holds promise for delaying the decline in cognition, mood, and daily function that accompanies the progression of Alzheimer's disease, and may be particularly useful as a supplement for pharmacological approaches during later stages of this disorder. A larger trial is warranted.

PubMed Disclaimer

References

    1. Swerdlow RH Pathogenesis of Alzheimer's disease. Clin Interv Aging. 2007;2:347-359. - PMC - PubMed
    1. Shah S., Reichman WE Treatment of Alzheimer's disease across the spectrum of severity. Clin Interv Aging. 2006;1:131-142. - PMC - PubMed
    1. Burns A., Gauthier S., Perdomo C. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2007;22:806-812. - PubMed
    1. Feldman HH, Schmitt FA, Olin JT Memantine MEM-MD-02 Study Group. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment . Alzheimer Dis Assoc Disord. 2006;20:263-268. - PubMed
    1. Johannsen P. Medical treatment of Alzheimer's disease. Ugeskr Laeger. 2006;168:3424-3429. - PubMed

Publication types